Maternal opioid treatment: Human experimental research (MOTHER) study: Maternal, fetal and neonatal outcomes from secondary analyses

Addiction

Volumn 107, Issue SUPPL.1, 2012, Pages 1-4

  Bandstra, Emmalee S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Methadone; Neonatal abstinence syndrome; Opioids; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE;

ADOLESCENT; ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; FEMALE; HUMAN; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868114070     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04059.x     Document Type: Editorial

References (20)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2012. Vienna, Austria: UNODC; 2012, p. 1-112.
2. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: National Findings. Series H-41, HHS Publication no. (SMA) 11-4658. Rockville, MD: SAMHSA; 2011.
3. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-151.
4. Jones H. E., Heil S. H., Baewert A., Arria A. M., Kaltenbach K., Martin P. R. etal. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012; 107 (Suppl. 1): 5-27.
5. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
6. Jones H. E., Fischer G., Heil S. H., Kaltenbach K., Martin P. R., Coyle M. G. etal. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues and lessons learned. Addiction 2012; 107 (Suppl. 1): 28-35.
7. Salisbury A. L., Coyle M. G., O'Grady K. E., Heil S. H., Martin P. R., Stine S. M. etal. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012; 107 (Suppl. 1): 36-44.
8. Kaltenbach K., Holbrook A. M., Coyle M. G., Heil S. H., Salisbury A. L., Stine S. M. etal. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on agonist medication. Addiction 2012; 107 (Suppl. 1): 45-52.
9. Gaalema D. E., Scott T. L., Heil S. H., Coyle M. G., Kaltenbach K., Badger G. J. etal. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction 2012; 107 (Suppl. 1): 53-62.
10. Coyle M. G., Salisbury A. L., Lester B. M., Jones H. E., Lin H., Graf-Rohrmeister K. etal. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012; 107 (Suppl. 1): 63-73.
11. Benningfield M. M., Dietrich M. S., Jones H. E., Kaltenbach K., Heil S. H., Stine S. M. etal. Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. Addiction 2012; 107 (Suppl. 1): 74-82.
12. Holbrook A. M., Baxter J. K., Jones H. E., Heil S. H., Coyle M. G., Martin P. R. etal. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction 2012; 107 (Suppl. 1): 83-90.
13. McNicholas L. F., Holbrook A. M., O'Grady K. E., Jones H. E., Coyle M. G., Martin P. R., et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction 2012; 107 (Suppl. 1): 91-97.
14. McCarthy J. J. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012; 25: 109-112.
15. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012; 25: 1197-1201.
16. Newman R. G., Gevertz S. G. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis 2011; 30: 318-322.
17. Jones H. E., Heil S. H., Kaltenbach K., Stine S., Coyle M., Arria A. etal. Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis 2012; doi: 10.1080/10550887.2012.736289.
18. Sackett D. L., Rosenberg W. M., Gray J. A., Haynes R. B., Richardson W. S. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-72.
19. Jones H. E., Finnegan L. P., Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012; 72: 747-757.
20. Hudak M. L., Tan R. C.; Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012; 129: e540-560.